NADAC acquisition cost data for EMGALITY 120 MG/ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00002237701 | $630.62 | 2022-01-01 | Rx |
| 00002237711 | $630.62 | 2022-01-01 | Rx |
| 00002237701 | $630.62 | 2022-01-01 | Rx |
| 00002237711 | $630.62 | 2022-01-01 | Rx |
| 00002237701 | $630.62 | 2022-01-01 | Rx |
| 00002237711 | $630.62 | 2022-01-01 | Rx |
| 00002237701 | $630.62 | 2022-01-01 | Rx |
| 00002237711 | $630.62 | 2022-01-01 | Rx |
| 00002237701 | $630.62 | 2022-01-01 | Rx |
| 00002237711 | $630.62 | 2022-01-01 | Rx |
Generic: Galcanezumab-Gnlm | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $40.7M | 57,344 | 15,243 | $588.60 |
| 2020 | $112.7M | 151,487 | 29,849 | $625.57 |
| 2021 | $147.1M | 186,809 | 34,168 | $658.74 |
| 2022 | $183.6M | 218,874 | 39,270 | $694.70 |
| 2023 | $229.3M | 262,291 | 46,469 | $716.06 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $16.2M | 17,727 | 3,526 |
| California | $14.7M | 16,638 | 3,067 |
| Pennsylvania | $13.2M | 16,194 | 2,701 |
| New York | $11.2M | 13,250 | 2,379 |
| Texas | $10.8M | 12,149 | 2,397 |
| North Carolina | $9.7M | 11,144 | 2,076 |
| Indiana | $8.4M | 9,299 | 1,694 |
| Ohio | $8.4M | 9,662 | 1,708 |
| Tennessee | $8.3M | 9,562 | 1,815 |
| Michigan | $7.3M | 8,606 | 1,579 |
| Missouri | $7.1M | 8,100 | 1,424 |
| Kentucky | $6.9M | 7,738 | 1,440 |
| Wisconsin | $6.8M | 8,074 | 1,343 |
| Georgia | $6.4M | 7,221 | 1,298 |
| Arizona | $6.1M | 6,740 | 1,296 |
| Illinois | $5.8M | 6,495 | 1,160 |
| Colorado | $5.2M | 5,387 | 992 |
| Alabama | $5.1M | 6,231 | 1,055 |
| Virginia | $5.0M | 5,538 | 1,122 |
| Massachusetts | $4.8M | 5,763 | 990 |
| Minnesota | $4.7M | 5,401 | 932 |
| Washington | $4.6M | 5,013 | 884 |
| South Carolina | $4.0M | 4,212 | 828 |
| Connecticut | $4.0M | 4,588 | 752 |
| Arkansas | $3.7M | 4,155 | 749 |
| Louisiana | $3.7M | 4,403 | 780 |
| New Jersey | $3.1M | 3,498 | 674 |
| Oklahoma | $3.1M | 3,590 | 659 |
| Iowa | $2.7M | 3,006 | 558 |
| Puerto Rico | $2.7M | 3,650 | 546 |
| Maryland | $2.6M | 2,714 | 545 |
| Oregon | $2.3M | 2,608 | 448 |
| Mississippi | $2.1M | 2,390 | 462 |
| Idaho | $1.8M | 2,185 | 376 |
| New Hampshire | $1.8M | 2,087 | 372 |
| Nebraska | $1.7M | 2,195 | 347 |
| Kansas | $1.6M | 1,847 | 359 |
| Utah | $1.5M | 1,622 | 347 |
| Nevada | $1.2M | 1,413 | 261 |
| New Mexico | $1.2M | 1,394 | 254 |
| Maine | $1.1M | 1,141 | 208 |
| Montana | $1.0M | 1,240 | 198 |
| West Virginia | $1.0M | 1,156 | 252 |
| Delaware | $941.9K | 1,093 | 183 |
| Vermont | $892.8K | 690 | 166 |
| South Dakota | $651.7K | 747 | 126 |
| Rhode Island | $637.8K | 822 | 148 |
| North Dakota | $571.9K | 707 | 117 |
| Wyoming | $323.8K | 361 | 65 |
| District of Columbia | $277.5K | 298 | 67 |
| Hawaii | $252.9K | 278 | 54 |
| Alaska | $114.3K | 134 | 27 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.